Trial watch: TLR3 agonists in cancer therapy - Sorbonne Université
Journal Articles OncoImmunology Year : 2020

Trial watch: TLR3 agonists in cancer therapy

Abstract

Toll-like receptor 3 (TLR3) is a pattern recognition receptor that senses exogenous (viral) as well as endogenous (mammalian) double-stranded RNA in endosomes. On activation, TLR3 initiates a signal transduction pathway that culminates with the secretion of pro-inflammatory cytokines including type I interferon (IFN). The latter is essential not only for innate immune responses to infection but also for the initiation of antigen-specific immunity against viruses and malignant cells. These aspects of TLR3 biology have supported the development of various agonists for use as stand-alone agents or combined with other therapeutic modalities in cancer patients. Here, we review recent preclinical and clinical advances in the development of TLR3 agonists for oncological disorders.
Fichier principal
Vignette du fichier
Trial watch TLR3 agonists in cancer therapy.pdf (766.25 Ko) Télécharger le fichier
Origin Publication funded by an institution
Loading...

Dates and versions

hal-02881350 , version 1 (25-06-2020)

Identifiers

Cite

Julie Le Naour, Lorenzo Galluzi, Laurence Zitvogel, Guido Kroemer, Erika Vacchelli. Trial watch: TLR3 agonists in cancer therapy. OncoImmunology, 2020, 9 (1), pp.1771143. ⟨10.1080/2162402X.2020.1771143⟩. ⟨hal-02881350⟩
28 View
197 Download

Altmetric

Share

More